Josef Mališ

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study

Ruth Ladenstein, Dominique Valteau‐Couanet, Penelope Brock et al. · Journal of Clinical Oncology · 2010 · 129 citations

Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study

Keith Holmes, Ulrike Pötschger, Andrew D.J. Pearson et al. · Journal of Clinical Oncology · 2020 · 117 citations · Full text

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study

Daniel A. Morgenstern, Ulrike Pötschger, Lucas Moreno et al. · Pediatric Blood & Cancer · 2018 · 74 citations · Full text

Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)

Angela Bellini, Ulrike Pötschger, Virginie Bernard et al. · Journal of Clinical Oncology · 2021 · 73 citations · Full text